Form 4: Scholar Rock CMO Granted 34,482 Restricted Stock Units

Scholar Rock Holding Corp's Chief Medical Officer, Jing L. Marantz, was granted 34,482 restricted stock units, vesting over four years.

Summary

• Jing L. Marantz, Chief Medical Officer of Scholar Rock Holding Corp (SRRK), acquired 34,482 restricted stock units (RSUs).
• The transaction date for this acquisition was February 9, 2026.
• Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting.
• The RSUs will vest in four equal annual installments over four years, with the first installment vesting on January 15, 2027.
• Vesting is contingent upon the reporting person maintaining a service relationship with Scholar Rock Holding Corp on each vesting date.
• Following this transaction, Jing L. Marantz beneficially owns a total of 130,169 securities, comprising 24,974 shares of common stock and 105,195 RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management interests with long-term shareholder value. It signals stability in leadership.

Positives

• The grant of restricted stock units aligns the Chief Medical Officer's long-term interests with those of shareholders, incentivizing sustained performance.
• The four-year vesting schedule promotes executive retention, ensuring continuity in key leadership roles.

Negatives

• The issuance of new restricted stock units will result in a minor dilutive effect on existing shareholders upon vesting, though this is a standard component of executive compensation.

Risks

• The vesting of the RSUs is subject to the reporting person's continued service relationship with the Issuer, meaning the full benefit is not guaranteed if employment ceases.
• The value of the RSUs upon vesting is dependent on the future market price of Scholar Rock Holding Corp's common stock, introducing market risk.

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule indicates a long-term commitment from the Chief Medical Officer to the company's future performance and strategic objectives, contingent on continued employment.

Industry Context

StockSavvy.ai notes that granting restricted stock units to key executives is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is widely used to attract, retain, and motivate top talent by aligning their financial incentives with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are a standard component of executive compensation packages across the biotech sector, comparable to practices at companies like Moderna, Biogen, and Vertex Pharmaceuticals, which frequently use similar equity incentives to retain scientific and medical leadership.
• The structure of four annual installments is typical for long-term incentive plans, ensuring sustained commitment over several years, a common benchmark in the industry for executive retention.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but also increased alignment of executive interests with long-term company performance.
• Employees: Signals stability in executive leadership and a commitment to retaining key personnel.
• Management: Provides long-term incentive and compensation tied to the company's stock performance.

Next Steps

• The first annual installment of the granted RSUs is scheduled to vest on January 15, 2027, provided the Chief Medical Officer remains employed by the Issuer.
• Subsequent annual installments will vest annually thereafter, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant of restricted stock units. While it aligns management incentives with shareholder interests and aids retention, it does not present new fundamental information that would significantly alter the company's valuation or warrant a change in investment recommendation. It is a standard operational event.

Keywords

Scholar Rock Holding Corp, SRRK, Restricted Stock Units, RSU Grant, Insider Transaction, Executive Compensation, Jing L. Marantz, Chief Medical Officer, SEC Form 4